Prasugrel

Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

Original languageEnglish (US)
Pages (from-to)1627-1633
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume15
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

clopidogrel
Acute Coronary Syndrome
Aspirin
Stents
Thrombosis
Blood Platelets
Clinical Trials
Therapeutics
Prasugrel Hydrochloride

Keywords

  • Non-responsiveness
  • Platelet inhibition
  • Prasugrel
  • Thienopyridine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2006). Prasugrel. Expert Opinion on Investigational Drugs, 15(12), 1627-1633. https://doi.org/10.1517/13543784.15.12.1627

Prasugrel. / Tantry, Udaya S.; Bliden, Kevin P.; Gurbel, Paul A.

In: Expert Opinion on Investigational Drugs, Vol. 15, No. 12, 12.2006, p. 1627-1633.

Research output: Contribution to journalArticle

Tantry, US, Bliden, KP & Gurbel, PA 2006, 'Prasugrel', Expert Opinion on Investigational Drugs, vol. 15, no. 12, pp. 1627-1633. https://doi.org/10.1517/13543784.15.12.1627
Tantry US, Bliden KP, Gurbel PA. Prasugrel. Expert Opinion on Investigational Drugs. 2006 Dec;15(12):1627-1633. https://doi.org/10.1517/13543784.15.12.1627
Tantry, Udaya S. ; Bliden, Kevin P. ; Gurbel, Paul A. / Prasugrel. In: Expert Opinion on Investigational Drugs. 2006 ; Vol. 15, No. 12. pp. 1627-1633.
@article{d076afb3a12d4809902dfbe325a5465f,
title = "Prasugrel",
abstract = "Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.",
keywords = "Non-responsiveness, Platelet inhibition, Prasugrel, Thienopyridine",
author = "Tantry, {Udaya S.} and Bliden, {Kevin P.} and Gurbel, {Paul A.}",
year = "2006",
month = "12",
doi = "10.1517/13543784.15.12.1627",
language = "English (US)",
volume = "15",
pages = "1627--1633",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Prasugrel

AU - Tantry, Udaya S.

AU - Bliden, Kevin P.

AU - Gurbel, Paul A.

PY - 2006/12

Y1 - 2006/12

N2 - Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

AB - Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyricline (a P2Y12 receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyricline derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y12 receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.

KW - Non-responsiveness

KW - Platelet inhibition

KW - Prasugrel

KW - Thienopyridine

UR - http://www.scopus.com/inward/record.url?scp=33845224320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845224320&partnerID=8YFLogxK

U2 - 10.1517/13543784.15.12.1627

DO - 10.1517/13543784.15.12.1627

M3 - Article

C2 - 17107286

AN - SCOPUS:33845224320

VL - 15

SP - 1627

EP - 1633

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -